Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Cancer and heart disease vaccines ‘ready by end of the decade:
Dr Paul Burton, the chief medical officer of pharmaceutical company Moderna, said he believes the firm will be able to offer such treatments for “all sorts of disease areas” in as little as five years.
https://www.theguardian.com/society/2023/apr/07/cancer-and-heart-disease-vaccines-ready-by-end-of-the-decade
MRNA-4157/V940, AN INVESTIGATIONAL PERSONALIZED MRNA CANCER VACCINE, IN COMBINATION WITH KEYTRUDA(R) (PEMBROLIZUMAB), RECEIVES PRIME SCHEME DESIGNATION FROM THE EUROPEAN MEDICINES AGENCY FOR ADJUVANT TREATMENT OF PATIENTS WITH HIGH-RISK STAGE III/IV MELANOMA FOLLOWING COMPLETE RESECTION
https://investors.modernatx.com/news/news-details/2023/MRNA-4157V940-an-Investigational-Personalized-MRNA-Cancer-Vaccine-in-Combination-With-KeytrudaR-Pembrolizumab-Receives-Prime-Scheme-Designation-From-the-European-Medicines-Agency-for-Adjuvant-Treatment-of-Patients-With-High-Risk-Stage-IIIIV-Melanoma-/default.aspx
First Citizens Bank & Trust Co. Increases Investment in Moderna Inc. Amid Growing Confidence in mRNA-based Medicine
First Citizens Bank & Trust Co. has increased its position in Moderna, Inc., investing a further $2,177,000 into the revolutionary healthcare company. Moderna’s approach to medicine is based on messenger ribonucleic acid (mRNA), which makes breakthroughs in areas such as prophylactic vaccines, cancer treatment and regenerative therapeutics possible. The investment by First Citizens Bank & Trust Co. highlights their confidence in the innovative capacity of Moderna’s work.
I
MODERNA FINALIZES AGREEMENT WITH THE GOVERNMENT OF THE REPUBLIC OF KENYA TO ESTABLISH AN MRNA MANUFACTURING FACILITY
in partnership with the Government of the Republic of Kenya, Moderna will build a state-of-the-art mRNA facility in Kenya to produce up to 500 million doses of vaccines each year. The Company expects the new facility to enable drug substance and drug product manufacturing for Kenya and the African continent. In addition, this facility will have surge capacity to rapidly scale and respond to public health emergencies on the continent and around the world.
Moderna is committed to advancing into clinical studies a portfolio of 15 vaccine programs targeting emerging or neglected infectious diseases by 2025, advancing vaccines that address current diseases of significant impact to low- and middle-income countries, and those that prepare for Disease X. Moderna will prioritize development efforts against pathogens identified as persistent global health threats, including HIV, tuberculosis (TB) and malaria, neglected tropical diseases and the priority pathogens of the World Health Organization and the Coalition for Epidemic Preparedness Innovations.
With this agreement, Moderna has commitments to establish mRNA manufacturing facilities in Kenya, the United States, Canada, Australia, and the United Kingdom
https://investors.modernatx.com/news/news-details/2023/Moderna-Finalizes-Agreement-with-the-Government-of-the-Republic-of-Kenya-to-Establish-an-mRNA-Manufacturing-Facility/default.aspx
Johnson & Johnson ducked out of the RSV vaccine race Wednesday, leaving Pfizer, GSK and Moderna to duke it out.
https://www.fiercebiotech.com/biotech/jj-scraps-phase-3-rsv-vaccine-infectious-disease-overhaul-continues
Moderna predicts the post-pandemic market will follow that of the flu. In the U.S. alone, about half of Americans go for flu shots
Moderna's pipeline includes more than 40 programs. Today, three candidates outside the coronavirus program are in phase 3 trials -- and close to the finish line. These are vaccine candidates for respiratory syncytial virus (RSV), cytomegalovirus (CMV), and flu. Moderna aims to file for regulatory approval of the RSV candidate in the first half of this year.
The company recently reported positive data from a phase 2 trial of its personalized cancer vaccine combined with Merck's Keytruda. In fact, the U.S. Food and Drug Administration even granted the combination a breakthrough therapy designation. This is meant to accelerate the development of promising products for serious conditions.
the future looks bright, with many huge potential growth drivers right around the corner!!!!!!
MODERNA TO HOST FOURTH ANNUAL VIRTUAL VACCINES DAY ON APRIL 11, 2023
news coming.......
In a sceptical era, understand this: vaccines do work - and our children need them:
in 1959, at the age of 29, the promising England footballer Jeff Hall died of polio. His death sent shock waves across Britain, and caused an immediate change in attitudes towards vaccination, from complacency to a sudden rush to clinics. A polio vaccine had been available for three years, but takeup was low. After Hall’s death, the demand was so high that vaccines had to be flown in from the US. As the Daily Express put it: “In the past 10 years over 3,000 people have died of polio in England and Wales. But it took the death of one footballer to get [people] pouring into the clinics.” More than half a century later, we may be returning to complacency when it comes to getting children vaccinated.
https://www.theguardian.com/commentisfree/2023/mar/27/vaccines-work-children-covid-decline-england
Moderna's gene therapy expansion picks up pace with $76M upfront Generation Bio collab
It's your fantasy, not mine.
The future is moving quickly....
How mRNA vaccines could target everything from cancer to the plague-
https://nypost.com/2023/03/25/how-mrna-vaccines-could-soon-target-cancer-the-plague/
Moderna CEO brazenly defends 400% COVID shot price hike, downplays NIH’s role
https://arstechnica.com/science/2023/03/moderna-ceo-says-us-govt-got-covid-shots-at-discount-ahead-of-400-price-hike/
FDA May Authorize Additional Covid-19 Booster Shots
Agency officials could make the decision on clearing another round for people at high risk within a few weeks
https://www.wsj.com/articles/fda-may-authorize-additional-covid-19-booster-shots-c85c0672
No good treatment goes unpunished for pharmaceutical companies these days, and Bernie Sanders will offer another example on Wednesday when he holds a political show trial of Moderna CEO Stéphane Bancel. His offense? Cooperating with the government to produce life-saving Covid vaccines.
The subject of the Vermont Senator’s hearing is Moderna’s plan to quadruple the price of its Covid vaccine to $110 to $130 per dose when U.S. government purchases stop. Pfizer has said it will charge a similar price after vaccines move to the commercial market, which is expected later this year.
But Mr. Sanders is specifically targeting Mr. Bancel because his company worked with the Trump Administration’s Operation Warp Speed (OWS) to accelerate its vaccine development. Mr. Bancel apparently should have known better than to work with the government.
Early in the Covid pandemic, Moderna received $900 million from OWS for trials to test its mRNA vaccine in partnership with the National Institutes of Health. Pfizer chose to go it alone because “when you get money from someone, that always comes with strings,” as CEO Albert Bourla explained in September 2020. No kidding.
Mr. Sanders claims that taxpayers paid to develop Moderna’s Covid vaccine, and the government thus should be able to dictate its price. That’s nonsense. Before the pandemic, Moderna developed its novel mRNA platform with $3.8 billion in private investment. In spring 2020, it raised another $1.3 billion in private capital to scale up manufacturing.
If not for the Moderna-OWS cooperation, the vaccine rollout would have been much slower. Moderna’s vaccine has proven more durable and protective against severe illness than Pfizer’s in real-world studies. Yet the Administration has consistently paid Pfizer $3 to $4 more per dose. As a result, Pfizer has received more than a billion dollars more from the government than Moderna.
Yet progressives are targeting Moderna as “a poster child for corporate greed,” to quote Mr. Sanders, because they believe this advances their view that pharma companies profit from government innovation and support. The truth is closer to the opposite. The government and public benefit from Moderna’s billions of dollars spent on research and development.
White House spokesperson Karine Jean-Pierre piled on by claiming Moderna’s price hike is “hard to justify” even as Biden officials hail the benefits of Covid vaccines and boosters. If they are as effective as public-health officials say, then the benefits from reducing hospitalizations among the elderly would more than exceed the new higher price.
Taxpayers were getting a bargain under the OWS contract that paid Moderna about $15 a dose. Even after the vaccine transitions to the commercial market, Moderna’s price will be lower than for such vaccines as GSK’s shingles shot ($183) or Merck’s pneumonia vaccine ($216), according to Centers for Disease Control and Prevention data.
Under the Affordable Care Act, Americans with private insurance won’t have to pay a penny out-of-pocket for the vaccines. Moderna will also offer free vaccines to the uninsured. So what’s the problem? Moderna will profit from its innovation. Oh no! Worse, Moderna’s profits will fund trials of other vaccines in development, including for cancer.
Life-saving vaccines and treatments undermine the political narrative that pharmaceutical companies are capitalist exploiters, a view also growing on the political right. That’s why Mr. Bancel is in the dock.
https://www.wsj.com/articles/bernie-sanders-moderna-stephane-bancel-covid-vaccine-price-6931a89a
Moderna Inc expects to price its COVID-19 vaccine at around $130 per dose in the U.S. going forward as purchases move to the private sector from the government, the company’s president Stephen Hoge said in an interview on Monday.
https://finance.yahoo.com/news/1-moderna-expects-price-covid-223318215.html
Moderna says it compensated US more than enough for Covid-19 shot partnership
On Wednesday, Moderna chief executive Stephane Bancel will testify before a Senate panel about the price the company will charge for its vaccine after the US government stops buying the shots, shifting that responsibility to the private market.
https://www.straitstimes.com/world/united-states/moderna-paid-the-us-more-than-enough-for-covid-shot-partnership-executive-says
$MRNA
Moderna also has a personalized cancer vaccine (PCV) candidate in phase 2 trials that it's developing with Merck. As of February 2023, the FDA granted that program a Breakthrough Therapy Designation, too, which means that it could experience compressed development timelines. If it starts to report promising late-stage data, that should provide yet another shot in the arm for mrna
shares.
money for all ....maybe
Commonwealth's research also estimated that the U.S. vaccination program saved the country $1.15 trillion "in medical costs that would otherwise have been incurred."
Next week, Moderna CEO Stéphane Bancel will testify before the Senate Health, Education, Labor, and Pensions Committee on the price of his company's COVID-19 vaccine.
He'll face an unfriendly audience. Committee Chairman Sen. Bernie Sanders, I-Vt., claims that companies like Moderna profited off COVID at Americans' expense. He's eager to "rein in the greed of these pharmaceutical pandemic profiteers."
stay tuned>>>>>>>>>>
https://www.forbes.com/sites/sallypipes/2023/03/16/bernie-doesnt-get-healthcare-innovation/?sh=1b1e7031696e
These vaccine candidates for respiratory syncytial virus (RSV), cytomegalovirus (CMV), and flu are in phase 3 trials. So they're approaching the finish line. In fact, Moderna aims to file for regulatory approval of the RSV candidate by the end of the first half of this year.
$MRNA
our partner: Keytruda Unlocked: How Should Merck Proceed with Trials-
https://www.biospace.com/article/keytruda-unlocked-how-should-merck-proceed-with-keytruda-trials-/
About mRNA-4157/V940
Personalized cancer vaccines are designed to prime the immune system so that a patient can generate a tailored antitumor response specific to their tumor mutation signature. mRNA-4157/V940 is a novel investigational messenger ribonucleic acid (mRNA)-based personalized cancer vaccine consisting of a single synthetic mRNA coding for up to 34 neoantigens that is designed and produced based on the unique mutational signature of the patient's tumor. Upon administration into the body, the algorithmically derived and mRNA-encoded neoantigen sequences are endogenously translated and undergo natural cellular antigen processing and presentation, a key step in adaptive immunity.
mRNA-4157/V940 is being developed in combination with KEYTRUDA. mRNA-4157/V940 is designed to stimulate an immune response by generating specific T cell responses based on the unique mutational signature of a patient's tumor. KEYTRUDA is an immunotherapy that works by increasing the ability of the body's immune system to help detect and fight tumor cells.
Moderna and Merck plan to initiate a Phase 3 study in adjuvant melanoma in 2023 and expect to rapidly expand to additional tumor types, including non-small cell lung cancer.
The two abstract titles are:
Presentation #CT001: A personalized cancer vaccine, mRNA-4157, combined with pembrolizumab versus pembrolizumab in patients with resected high-risk melanoma: Efficacy and safety results from the randomized, open- label Phase 2 mRNA-4157-P201/Keynote-942 trial. Harnessing the Immune System in the Clinic.
Session: Clinical Trials Plenary; Sunday, April 16 at 1:00-3:00 PM ET.
Presenter: Dr. Jeffrey S. Weber
Poster Session #CT224: Evaluation of minimal residual disease as a predictive biomarker of recurrence free survival in high-risk melanoma patients treated with a combination of mRNA-4157, a personalized cancer vaccine, and pembrolizumab.
Session: Phase II Clinical Trials 2; Tuesday, April 18 at 9:00 AM - 12:30 PM ET.
Author: Dr. Ryan J. Sullivan
stay tuned....
$MRNA
CAMBRIDGE, MA / ACCESSWIRE / March 14, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that two abstracts on mRNA-4157/V940 an investigational mRNA personalized cancer vaccine, have been accepted for presentation at the 2023 American Association of Cancer Research (AACR) Annual Meeting being held April 14-19 in Orlando, FL. mRNA-4157/V940 is being jointly developed by Moderna and Merck, known as MSD outside of the United States and Canada.
https://investors.modernatx.com/news/news-details/2023/Moderna-Announces-Phase-2-Data-on-mRNA-4157V940-an-Investigational-mRNA-Personalized-Cancer-Vaccine-to-be-Presented-at-the-2023-AACR-Annual-Meeting/default.aspx
It is prepared with veal or lamb.
Raw materials matter in mRNA vaccine and therapeutic development
https://www.fiercebiotech.com/sponsored/raw-materials-matter-mrna-vaccine-and-therapeutic-development
Study your lesson next time:
https://www.modernatx.com/research/product-pipeline
just search......Follow our instructions and you're done.
2 Top Biotech Stocks to Buy In March and Hold Forever:
$MRNA it has four programs in phase 3 clinical trials, and nine programs in phase 2 trials
Maravai LifeSciences is a biotech that's upstream of Moderna. It sells the nucleic acids that Moderna and other mRNA drug developers like BioNTech and Pfizer need to do research, conduct clinical trials, and manufacture doses of their mRNA medicines. That means if its customers are going to go big on their mRNA pipelines over the next decade, Maravai stands to make a ton of money along the way whether its customers succeed in commercializing new drugs or not.
very nice$
https://www.fool.com/investing/2023/03/13/2-biotech-stocks-to-buy-in-march-and-hold-forever/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article
Moderna may seek the FDA’s accelerated approval for its personalized cancer vaccine, the company’s president, Stephen Hoge, said Monday at Cowen’s 43rd Annual Healthcare Conference in Boston.
https://www.biospace.com/article/moderna-eyes-accelerated-approval-for-mrna-cancer-vaccine/
Moderna eyes human testing of mpox, bird flu vaccines this year: ‘They’re really for public health’
https://finance.yahoo.com/news/moderna-eyes-human-testing-mpox-180343041.html
Accelerated approval incoming? Moderna 'hopeful' for personalized cancer vaccine......
https://endpts.com/accelerated-approval-incoming-moderna-hopeful-for-personalized-cancer-vaccine/
(nice)------- stay tuned------
Reason to buy: It has oodles of cash to invest in long-term growth
For a biotech, there's nothing better than having a lot of money to spend on stuff like pioneering new pipeline programs, doing more preclinical research, and building additional platform capabilities. Biotech is a risky business, and the more money a company has, the more chances it has to hit a home run -- and the more times it can safely strike out without endangering its future.
On that note, Moderna ended 2022 with a mind-boggling $18.2 billion in cash, equivalents, and investments, and it plans to spend only $4.5 billion on research and development (R&D) in 2023. That means it could continue to spend like wild even if its earnings were to somehow drop to zero, which they won't.
It also means that the company will be able to easily acquire any promising upstarts that management thinks will be useful, not to mention opening the door to direct investments in key suppliers like Maravai LifeSciences if the need arises.
And that's why having a lot of cash is yet another reason to invest.
Reason to sell: Revenue is going to keep crashing for a while
https://www.fool.com/investing/2023/03/06/2-reasons-to-buy-moderna-stock-1-reason-to-sell/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article
we are here to make money$$$$$$$$$
I don't care what you write
NOVAX
$MRNA
we are coming $MRNA
(BLA) for mRNA-1345 to the FDA in the first half of 2023
FDA advisors recommend first-ever RSV vaccine from Pfizer, despite possible Guillain-Barre risks
https://www.nbcdfw.com/news/business/money-report/fda-advisors-recommend-pfizer-rsv-vaccine-for-older-adults-despite-possible-guillain-barre-risks/3204213/
Four Aces!
relax$
LOL
Moderna, on its back foot, reassures investors on flu vaccine after mixed phase 3 data
https://www.fiercebiotech.com/biotech/moderna-dinged-lukewarm-flu-data-waits-efficacy-readout-charting-regulatory-course